Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Fiche publication
Date publication
juillet 2018
Journal
Annales d'endocrinologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Lien Pubmed
Résumé
The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.
Mots clés
Adrenal failure, Diabetes, Dyslipidemia, Dysthyroidism, Hypophysitis, Immunotherapy, MTOR inhibitors, Tyrosine kinase inhibitors
Référence
Ann. Endocrinol. (Paris). 2018 Jul 11;: